Cephalexin for Dogs Dosage Calculator

Cephalexin is the workhorse oral antibiotic of canine dermatology. As a first-generation cephalosporin it blocks bacterial cell wall cross-linking by binding penicillin-binding proteins, and it is reliably active against Staphylococcus pseudintermedius, the coagulase-positive staphylococcus responsible for the great majority of canine superficial pyoderma. Killing is time-dependent, so the objective is to hold plasma concentration above the organism's minimum inhibitory concentration for a large share of the dosing interval; that pharmacodynamic fact drives the standard canine regimen of 22 to 30 mg per kilogram every 12 hours, escalated to every eight hours for bone and joint infection. A 23 kg dog therefore receives roughly 500 to 700 mg per dose, which maps conveniently onto the 250, 500 and 750 mg tablet strengths. Duration is where practice has shifted most. For superficial pyoderma, dermatology guidance is to continue treatment about seven days past clinical resolution, which usually means three weeks or more, while deep pyoderma and osteomyelitis may need six weeks or longer. For simple bacterial cystitis the direction of travel has been the opposite: current infectious disease guidance favours short courses of three to five days with a first-line agent, and cephalexin is not the preferred first choice there. Roughly 5 to 10 percent of dogs develop vomiting, soft stool or inappetence, usually mitigated by giving the dose with food. Dogs with a documented penicillin or cephalosporin reaction should avoid it, and repeated empirical courses without culture select for methicillin-resistant S. pseudintermedius, now common enough that susceptibility testing is recommended for anything recurrent.

Cephalexin reached veterinary medicine as a borrowed human drug. After first-generation cephalosporins entered human practice in the late 1960s, small animal clinicians adopted the oral form for pyoderma because it was inexpensive, reasonably well accepted by dogs, and active against the staphylococci that dominate canine skin disease. For decades that use was entirely off-label, with dose ranges assembled from pharmacokinetic studies and formulary consensus rather than from a licensed canine indication, until veterinary-specific cephalexin products such as Rilexine were approved for canine secondary superficial pyoderma, giving the indication both a label and a validated dose. The microbiology underneath was rewritten over the same period. The organism responsible for canine pyoderma was called Staphylococcus intermedius for years, until molecular work published in 2005 by Devriese and colleagues split that group and established Staphylococcus pseudintermedius as the true canine pathogen, forcing laboratories to reinterpret older susceptibility data. Methicillin-resistant strains of the species then spread rapidly through the 2000s, and because methicillin resistance confers resistance to all beta-lactams including cephalexin, the profession moved toward formal stewardship. The International Society for Companion Animal Infectious Diseases published diagnosis and treatment guidelines for superficial bacterial folliculitis in 2014 and urinary tract infection guidelines in 2011, updated in 2019, which together reframed cephalexin as a sound first-line empirical choice for skin but not for lower urinary tract infection, and emphasised culture-directed therapy for recurrent disease.